Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Pharma companies undergoing critical transformation

By Liu Zhihua | China Daily | Updated: 2019-08-14 10:18
Share
Share - WeChat
A pharmacist picks medicines at a smart pharmacy of the First People's Hospital in Lianyungang, Jiangsu province. [Photo by Geng Yuhe/For China Daily]

China's pharmaceutical industry is undertaking a critical transformation toward high-quality and innovation-focused development, reflected by the explosion of new drug and clinical trial approvals in recent years, according to global consultancy firm McKinsey.

The transformation is being driven by factors such as a rapidly aging society, higher healthcare demands, drug regulation reforms, and increased investment inflows, said McKinsey.

"Healthcare is one of the most exciting sectors in China, growing above 10 percent annually," said Franck Le Deu, a senior partner at McKinsey.

"We expect more and more new drugs will come from Chinese companies."

He made the remarks during a media conference recently in Beijing and stressed China's faster approval process for clinical trials and new drugs, and the"4+7" volume-based tendering policy, are having a big impact on the pharmaceutical market structure in China.

In late 2018, Chinese authorities launched a national centralized procurement pilot program in four municipalities and seven local cities, commonly known as the 4+7 volume-based tendering policy, with an aim to slash drug prices and deepen reforms in the healthcare sector.

Earlier this month, the National Healthcare Security Administration issued a notice to extend the pilot work to more cities and provinces.

In the first round of the pilot program in early 2019, 31 drugs were listed for centralized procurement across all public hospitals in the 11 cities, and a successful bidder on a particular drug had the entire guaranteed purchase amount.

In practice, centralized procurement will be about 60 percent to 70 percent of the annual drugs purchased by public hospitals in the pilot regions, according to an article published on the State Council's website.

The centralized procurement is open to all approved companies that can produce drugs on the procurement list in the Chinese mainland. However, a selected drug, if a generic, must pass the consistency evaluation on quality and effectiveness against its original drug.

Clinical effects, adverse reactions, and batch stability of the drugs will be considered during the tendering, and their consistency will be the main criteria for evaluation, while production capacity and stability of the supplier will also be considered, the article said.

Zhou Gaobo, a partner at the firm, said the new landscape in China's pharmaceutical market has been contoured by government reforms. He urged Chinese companies to upgrade production and management for better cost control, increased product quality and higher production capacities, as well as to invest heavily on research and development to transition more to innovative drugs, if they want to survive the fierce competition.

The new environment also offers new standout chances for competent companies, he said.

Since 2016, investment in China's medical and pharmaceutical sector has reached $103 billion, studies from the company showed.

The company's studies also showed new pharmaceutical products are being brought to the China market faster due to related policy reforms, and more are from Chinese companies.

In 2016, only 17 percent of new drug applications in China were granted fast-track review, and in 2018, the figure rose to 74 percent.

New drugs approved in 2016,2017, 2018 and the first half of 2019 were respectively six, 41, 54 and 22, among which an increasing number is from Chinese companies in recent years.

New drugs approved from Chinese pharmaceutical companies were respectively three, one, nine, and four, for 2016, 2017, 2018 and the first half of 2019.

According to Hou Lei, also a partner at the firm, China's innovation capacity in the pharmaceutical sector has increased considerably since 2015, in terms of registration administration, market entrance, investments, talents, local innovation, and internationalization.

"Most Chinese companies start with generics as a market follower, and now many are trying to flip their product portfolios for more innovative drugs with increased efforts," she said.

"There have been me-too and me-better drugs from Chinese companies, and it is only a matter of time before Chinese companies produce first-in-class and best-in-class drugs."

The average pipelines of Chinese mainland biotech companies that applied for listing in Hong Kong in 2018 were 10, more than that of foreign biotech companies that floated shares on Nasdaq that year, which was four, she said.

However, the experts all said as the market landscape changes, Chinese pharmaceutical companies are faced with a series of challenges to become more competent to survive.

The challenges include how to foster research and development capabilities for high-quality products, digitalization, and optimization in organization and management.

Chen Qiulin, deputy director of the Health Industry Development Research Center at the Chinese Academy of Social Sciences, also said the Chinese pharmaceutical market's increasing emphasis on quality and cost-efficiency is driving local companies to focus more on innovation-driven development, and enhance their innovation and R&D capacities, although it is not an easy task.

Jiang Xueqing contributed to the story.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产区香蕉精品系列在线观看不卡| 成年女人免费观看视频| 免费在线观看一区| 黄色a三级免费看| 在线精品小视频| 中文字幕日韩视频| 欧美丰满熟妇XXXX性| 免费国产美女爽到喷出水来视频| 顶级欧美色妇xxxxx| 国产美女久久精品香蕉69| 一级特黄性色生活片录像| 日本理论片午午伦夜理片2021| 亚洲国产精彩中文乱码av| 男生女生一起差差很痛| 国产一区二区三区手机在线观看| 五月天婷婷综合网| 国模极品一区二区三区| 一本大道在线无码一区| 日本理论片午午伦夜理片2021| 亚洲人成网站在线观看播放青青| 狠狠综合久久综合88亚洲| 啊好深好硬快点用力别停免费视频| 黄色网站在线观看视频| 国产精品网站在线观看免费传媒| 国产成人精品综合在线观看| 国产大学生粉嫩无套流白浆| 亚洲毛片基地日韩毛片基地| 亚洲伊人成无码综合网| 久久精品免费一区二区喷潮| 中国一级全黄的免费观看| t66y最新地址| 88aa四虎影成人精品| 黄网站色视频免费观看| 老司机亚洲精品| 火车上荫蒂添的好舒服视频| 日本成人在线免费| 国产成人黄色小说| 2022男人天堂| 大学生美女毛片免费视频| 一级毛片**不卡免费播| 无码免费一区二区三区免费播放|